"Xijiang Project" Screening Cohort for NPC

Condition(s) studied

Investigational drug(s) / intervention(s)

EBV antibodies test: Test for VCA-IgA, EBNA1-IgA, EA-IgA, Zta-IgA, Rta-IgG and P85-Ab in nasopharyngeal brushing and plasma in plasma, saliva and nasopharyngeal brushing.

EBV DNA test: quantitative polymerase chain reaction, methylation sequencing and target sequencing of EBV DNA in nasopharyngeal brushing, saliva and plasma.

epidemiological information survey: epidemiological information survey including basic conditions, dietary and lifestyle habits, social, geographical, environmental, and other information.

Clinical examinations for high-risk participants: nasopharyngoscopy, head and neck MRI.

EBV and human genetic sequencing: EB virus and human genetic sequencing for plasma, etc.

Study summary

The purpose of this study is to establish a comprehensive and integrated nasopharyngeal carcinoma screening cohort, which includes an epidemiological information database containing basic information, gender, age, ethnic and family history, dietary and lifestyle habits, and geographical environmental factors; a biobank of blood, tissue fluid, swabs, etc., for Epstein-Barr virus, tumors, and genetics; a clinical examination database including nasopharyngoscopy, imaging, pathology, and other examinations; and databases of Epstein-Barr virus and human genetic sequencing, etc.

Eligibility

Primary outcome measure(s)

• A data platform for an NPC screening cohort — At screening, 3 years and 10 years thereafter
  A data platform, including an NPC epidemiological information database based on the gender, age, ethnicity, dietary and lifestyle habits, and geographical environmental factors, a biobank based on various samples and screening test results, and a clinical examination database based on nasopharyngoscopy, head and neck MRI, and a database for EB virus and human genetic sequencing information.

Trial sites (1)

More Ming-Yuan Chen trials in China

Other trials for the same condition